Thus, restraining the secretion of MMP2 and CAFs activation inducers by tumour cells [67], cabozantinib would avoid the release by CAFs of pro–motility (SDF1) or ECM remodelling-stimulating (HGF) factors [68]. Here, MMP2 is linked to neoplasm.